Loading
companiesCompany
Volpara Health
Volpara Health made software that measures breast density from mammograms and helps clinics manage breast cancer risk and screening quality. The New Zealand company was acquired by Korean AI firm Lunit in 2024 and now operates under the Lunit brand.
Overview
Volpara Health Technologies, founded in Wellington, New Zealand, developed AI software for breast screening: Volpara Scorecard provides objective volumetric breast density assessment from mammograms to support supplemental screening decisions, Risk Pathways manages breast cancer risk assessment and high-risk patient workflows, and Patient Hub supports patient engagement, alongside quality tools for mammography positioning and dose. Lunit, the Seoul-listed AI cancer diagnostics company (KRX: 328130), completed its acquisition of Volpara in 2024 and in November 2025 announced that Volpara now operates under the Lunit brand, with the combined business serving more than 10,000 sites in over 65 countries. The Scorecard and Risk Pathways products are now sold as part of Lunit's cancer screening portfolio, and the volparahealth.com domain redirects to lunit.io.
Headquarters
Wellington, NZ
Funding
All startupsAcquiredAcquired by Lunit
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Lunit's November 2025 release states the acquisition of Volpara Health Technologies was completed in 2024; value not stated in the fetched source. | 2024 | undisclosed | prnewswire.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Website
Notes
top- Wellington HQ is from the caller's hint and general knowledge; the fetched Lunit release does not state Volpara's location. The original acquisition announcement (Dec 2023) and completion release (May 2024) with the deal value could not be located on Lunit's media hub. Lunit itself is already in the graph.
Similar pages
- CompanyTherapixel
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- IdeaSet each woman's mammogram interval from her last mammogram, using AI risk
Shares Lunit, Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC).
- CompanyKheiron Medical Technologies
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- TreatmentLunit INSIGHT MMG
Shares Lunit, Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC).
- TreatmentTranspara
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- TreatmentProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- JournalJournal of breast imaging
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
Software that measures breast density and image quality from mammograms, used to drive supplemental screening pathways.